You are here

DESIGNMEDIX, INC.

Company Information
Address
2828 SW Corbett Ave Ste 114
Portland, OR 97201-4811
United States



Information

UEI: N/A

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    Amount: $353,902.00

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the worl ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  2. Preclinical development of novel small molecule malaria drugs that overcome drug

    Amount: $2,983,056.00

    DESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and ...

    STTRPhase II2014Department of Health and Human Services National Institutes of Health
  3. Optimization of a novel antimalarial drug candidate for plant-scale synthesis

    Amount: $102,614.00

    DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worl ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  4. Preclinical development of novel small molecule malaria drugs that overcome drug

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical develop ...

    STTRPhase I2011Department of Health and Human Services National Institutes of Health
  5. Designed Antimalarial Agents Overcoming Chloroquine-Resistance

    Amount: $1,327,610.00

    DESCRIPTION (provided by applicant): DesignMedix has developed a novel class of compounds to address the pressing need for an orally available, inexpensive drug to counter the spread of chloroquine-re ...

    STTRPhase II2009Department of Health and Human Services National Institutes of Health
  6. Designed Antimalarial Agents Overcoming Chloroquine-Resistance

    Amount: $103,876.00

    DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address ...

    STTRPhase I2007Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government